Kilpatrick Townsend managed the global License, Development and Commercialization Agreement between Biotest AG (Biotest), a German publicly traded biotechnology company, and Abbott Laboratories (Abbott) for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million. Additional milestone payments total $395 million, and Biotest will receive royalties thereafter on the sale of commercial products, bringing the total value of the deal well over $500 million.

BT-061 is currently in Phase II clinical trials for Rheumatoid Arthritis (RA) and psoriasis, with pre-clinical studies underway to study its potential use in other immune-related diseases. CD4 is expressed on T-cells and is involved in T-cell mediated modulation of immune responses. BT-061 is a humanized monoclonal antibody that works by activating the body’s T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive immune reactions. Unlike other anti-CD4 antibodies that have been in development, BT-061 does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses.

Under the terms of the agreement, Abbott and Biotest will co-promote BT-061 in five major European markets (Germany, France, the United Kingdom, Italy and Spain). Abbott will have exclusive global rights to commercialize BT-061 outside those countries. In addition to the upfront fee of $85 million, and subject to achievement of certain development, regulatory, commercial and sales-based milestones, Biotest would be eligible to receive additional milestone payments from Abbott, potentially amounting to a total of $395 million, and royalties. Biotest will be responsible for the manufacture of initial clinical supply of BT-061, and the parties will share responsibility for commercial production.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Employment litigation for one of the largest U.S. forest products manufacturers
Successfully defended one of the largest U.S. forest products manufacturers against a former employee's allegations that his termination constituted more
General Electric Company and General Electric Capital Corporation v. Nantucket Funding LLC, et al.
Obtained a temporary restraining order thwarting the misuse of the client's trademark by a loan services company seeking to enter into loan more
Acquisition services for AmSan, LLC
Served as buyer’s counsel for more than 40 acquisitions by AmSan, LLC, a major holding company organized to acquire and integrate custodial supply more
In the Matter of TALX Corporation
Represented TALX Corp. in connection with an antitrust enforcement action brought by the Federal Trade Commission (FTC) challenging a series of more